Evidence map›Paper›PMID 23162138›Full record

ArticleThe Journal of infectious diseases2013

Quinine treatment selects the pfnhe-1 ms4760-1 polymorphism in Malian patients with Falciparum malaria.

Aminatou Kone, Jianbing Mu, Hamma Maiga, Abdoul H Beavogui, Omar Yattara, Issaka Sagara, Mamadou M Tekete, Oumar B Traore, Antoine Dara, Souleymane Dama and 8 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. JAC-antimicrobial resistance · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Analysis of Plasmodium falciparum NaBMC infectious diseases · 2019
    Article
  6. Article
  7. Observational
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 4 countries.

Aminatou KoneMalaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy, and Odonto-Stomatology, University of Science, Techniques and Technology, Bamako, Mali.
Jianbing Mu
Hamma Maiga
Abdoul H Beavogui
Omar Yattara
Issaka Sagara
Mamadou M Tekete
Oumar B Traore
Antoine Dara
Souleymane Dama
Nouhoum Diallo
Aly Kodio
Aliou Traoré
Anders Björkman
Jose P Gil
Ogobara K Doumbo
Thomas E Wellems
Abdoulaye A Djimde
University of Bamako · MLNational Institute of Allergy and Infectious Diseases · USKarolinska University Hospital · SEUniversity of Algarve · PT

Funding

Malaria Drug Resistance and Disease VirulenceZIAAI000483 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI WELLEMS, THOMAS E · 2009 to 2025
$24.5M
Howard Hughes Medical Institute 55005502Intramural NIH HHS
6 · The paper itself

Abstract

backgroundThe mechanism of Plasmodium falciparum resistance to quinine is not known. In vitro quantitative trait loci mapping suggests involvement of a predicted P. falciparum sodium-hydrogen exchanger (pfnhe-1) on chromosome 13.

methodsWe conducted prospective quinine efficacy studies in 2 villages, Kollé and Faladié, Mali. Cases of clinical malaria requiring intravenous therapy were treated with standard doses of quinine and followed for 28 days. Treatment outcomes were classified using modified World Health Organization protocols. Molecular markers of parasite polymorphisms were used to distinguish recrudescent parasites from new infections. The prevalence of pfnhe-1 ms4760-1 among parasites before versus after quinine treatment was determined by direct sequencing.

resultsOverall, 163 patients were enrolled and successfully followed. Without molecular correction, the mean adequate clinical and parasitological response (ACPR) was 50.3% (n = 163). After polymerase chain reaction correction to account for new infections, the corrected ACPR was 100%. The prevalence of ms4760-1 increased significantly, from 26.2% (n = 107) before quinine treatment to 46.3% (n = 54) after therapy (P = .01). In a control sulfadoxine-pyrimethamine study, the prevalence of ms4760-1 was similar before and after treatment.

conclusionsThis study supports a role for pfnhe-1 in decreased susceptibility of P. falciparum to quinine in the field.

Indexed as

Polymorphism, Single NucleotideAmino Acid SequenceAntimalarialsDrug ResistanceHumansMalaria, FalciparumMaliMicrosatellite RepeatsMolecular Sequence DataPlasmodium falciparumQuinineSequence AlignmentSodium-Hydrogen ExchangersAntimalarialsgrowth factor-activatable Na-H exchanger NHE-1QuinineSodium-Hydrogen Exchangers

Identifiers

PMID23162138
PMCPMC3537444
OpenAlexW2104423823

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.